NCT02384382 - A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

May 3, 2019

Study Completion Date

May 3, 2019

Conditions

Prostate Carcinoma Metastatic to the BoneCastration Resistant Prostate Cancer

Interventions

DRUG

Enzalutamide

Trial Locations (5)

Karmanos Cancer Institute, Detroit

Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills

Wimr Pet/Ct, Madison

UW Clinical Sciences Center, Madison

Rutgers Cancer Institute of New Jersey, New Brunswick